MA33043B1 - Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie - Google Patents

Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie

Info

Publication number
MA33043B1
MA33043B1 MA34088A MA34088A MA33043B1 MA 33043 B1 MA33043 B1 MA 33043B1 MA 34088 A MA34088 A MA 34088A MA 34088 A MA34088 A MA 34088A MA 33043 B1 MA33043 B1 MA 33043B1
Authority
MA
Morocco
Prior art keywords
diabetes
type
sglt
inhibitor
hyperglycemia
Prior art date
Application number
MA34088A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Eickelmann
Michael Mark
Leo John Seman
Leo Thomas
Uli Broedl
Rolf Grempler
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008536&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33043(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33043B1 publication Critical patent/MA33043B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)

Abstract

L'invention porte sur le traitement ou la prévention d'un ou plusieurs états pathologiques parmi le diabète sucré de type 1, le diabète sucré de type 2, une intolérance au glucose et une hyperglycémie, à l'aide d'un inhibiteur SGLT-2. De plus, la présente invention porte sur des méthodes de prévention ou de traitement des troubles métaboliques et d'états pathologiques apparentés.
MA34088A 2009-02-13 2010-02-11 Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie MA33043B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15231809P 2009-02-13 2009-02-13
PCT/EP2010/051734 WO2010092123A1 (fr) 2009-02-13 2010-02-11 Inhibiteur sglt-2 pour le traitement du diabète sucré de type 1, du diabète sucré de type 2, d'une intolérance au glucose ou d'une hyperglycémie

Publications (1)

Publication Number Publication Date
MA33043B1 true MA33043B1 (fr) 2012-02-01

Family

ID=42008536

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34088A MA33043B1 (fr) 2009-02-13 2010-02-11 Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie

Country Status (28)

Country Link
US (8) US20110046087A1 (fr)
EP (1) EP2396005A1 (fr)
JP (3) JP5896276B2 (fr)
KR (2) KR20170028452A (fr)
CN (2) CN102316875A (fr)
AP (1) AP2011005795A0 (fr)
AR (1) AR075424A1 (fr)
AU (1) AU2010212865A1 (fr)
BR (1) BRPI1013640A2 (fr)
CA (1) CA2751833C (fr)
CL (1) CL2011001757A1 (fr)
CO (1) CO6410306A2 (fr)
EA (1) EA021796B1 (fr)
EC (1) ECSP11011275A (fr)
GE (1) GEP20146120B (fr)
HK (1) HK1203814A1 (fr)
IL (1) IL213723A0 (fr)
MA (1) MA33043B1 (fr)
MX (1) MX344264B (fr)
MY (1) MY161472A (fr)
NZ (1) NZ594485A (fr)
PE (1) PE20120002A1 (fr)
PH (1) PH12016501607A1 (fr)
SG (2) SG173587A1 (fr)
TN (1) TN2011000413A1 (fr)
TW (1) TWI478935B (fr)
UA (1) UA106365C2 (fr)
WO (1) WO2010092123A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103435581B (zh) * 2004-03-16 2015-08-19 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
RU2008113050A (ru) * 2005-09-08 2009-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US8039441B2 (en) * 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
US8283326B2 (en) * 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8603989B2 (en) * 2008-05-22 2013-12-10 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
MX2011000637A (es) 2008-07-15 2011-05-02 Theracos Inc Derivados deuretados de bencilbenceno y metodos de uso.
AP2011005672A0 (en) 2008-09-08 2011-04-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of CNS disorders.
CN102387783A (zh) * 2009-02-13 2012-03-21 贝林格尔.英格海姆国际有限公司 包含吡喃葡萄糖基二苯基甲烷衍生物的药物组合物、其药物剂型、其制备方法及其在患者中改善血糖控制的用途
WO2010092125A1 (fr) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp-iv et facultativement un autre agent antidiabétique et ses utilisations
NZ594567A (en) 2009-03-31 2013-12-20 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PT2486029E (pt) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
EP2483286B1 (fr) * 2009-09-30 2016-07-13 Boehringer Ingelheim International GmbH Procédé de préparation d'une forme cristalline de 1-chloro-4-( -d-glucopyranos-1-yl)-2-[4-((s)-tétrahydrofuran-3-yloxy)-benzyl]-benzène
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012020022A1 (fr) 2010-08-12 2012-02-16 Boehringer Ingelheim International Gmbh Dérivés de 6-cycloalkyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one et leurs utilisations en tant qu'inhibiteurs de pde9a
WO2012041898A1 (fr) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
BR112013031032A2 (pt) * 2011-06-03 2016-11-29 Boehringer Ingelheim Int inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102627535A (zh) * 2012-03-31 2012-08-08 天津药物研究院 含1,1-二苯基环丙基结构的化合物的制备方法
ES2959444T3 (es) * 2013-04-04 2024-02-26 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales equinos
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (fr) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
CA2812016A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
EA033286B1 (ru) 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек
EP4285995A3 (fr) * 2013-12-17 2024-02-28 Boehringer Ingelheim Vetmedica GmbH Un inhibiteur de sglt-2 pour le traitement des troubles métaboliques chez les félins
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
KR20220097538A (ko) * 2014-01-23 2022-07-07 베링거잉겔하임베트메디카게엠베하 개과 동물에서 대사 장애의 치료
NZ723781A (en) 2014-04-01 2022-09-30 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
WO2016036077A1 (fr) * 2014-09-02 2016-03-10 엘지전자 주식회사 Appareil de réception de diffusion générale, procédé d'exploitation d'un appareil de réception de diffusion générale, appareil imbriqué s'imbriquant avec un appareil de réception de diffusion générale, et procédé d'exploitation d'un appareil imbriqué
US10555958B2 (en) * 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
JP6561136B2 (ja) * 2015-04-30 2019-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ***機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
WO2016210008A1 (fr) * 2015-06-22 2016-12-29 Berg Llc Compositions comprenant de l'eno1 et leur utilisation dans des procédés de traitement de l'obésité ou de la surcharge pondérale et de réduction de la prise de poids
EP3341024A1 (fr) 2015-08-27 2018-07-04 Boehringer Ingelheim Vetmedica GmbH Compositions pharmaceutiques liquides comprenant des inhibiteurs de sglt-2
JP2018530592A (ja) 2015-10-15 2018-10-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性ミオパチーの治療に使用するためのｓｇｌｔ−２阻害剤
WO2019087239A1 (fr) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート Agent thérapeutique contre la néphropathie
US20210113561A1 (en) * 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR102408480B1 (ko) 2018-05-30 2022-06-10 이삼구 당뇨질환의 치료용 조성물
CN110141555A (zh) * 2019-06-21 2019-08-20 江苏豪森药业集团有限公司 一种恩格列净片及其制备方法
AU2021222297A1 (en) * 2020-02-17 2022-08-04 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
WO2022015743A1 (fr) * 2020-07-14 2022-01-20 GyanRx Sciences, Inc. Méthodes de traitement de calculs rénaux
KR20230112426A (ko) * 2022-01-20 2023-07-27 주식회사 대웅제약 이나보글리플로진을 포함하는 개과 동물의 비만 예방 또는 치료용 약학 조성물
KR20240045138A (ko) * 2022-09-29 2024-04-05 주식회사 대웅제약 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물
WO2024116198A1 (fr) * 2022-12-02 2024-06-06 Syri Research Private Limited Formulation liquide orale d'empagliflozine ou de son sel pharmaceutiquement acceptable

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
JP2004536047A (ja) * 2001-04-11 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー 糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
CN103435581B (zh) * 2004-03-16 2015-08-19 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
ES2314743T3 (es) * 2004-12-16 2009-03-16 Boehringer Ingelheim International Gmbh Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion.
WO2006089872A1 (fr) * 2005-02-23 2006-08-31 Boehringer Ingelheim International Gmbh Derives d'(hetero)arylethynyl-benzyd-benzene a substitution glucopyranosyle et leur utilisation en tant que cotransporteur 2 de glucose dependant de sodium (sglt2)
EP1874787B1 (fr) * 2005-04-15 2009-12-30 Boehringer Ingelheim International GmbH Derives de glucopyranosyl-substitue (heteroaryloxy-benzyl)-benzene utilises comme inhibiteurs de sglt
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007014894A2 (fr) * 2005-07-27 2007-02-08 Boehringer Ingelheim International Gmbh Derives de ((hetero)cycloalkylethynyl-benzyl)-benzene glucopyranosyl-substitutes, medicaments contenant ces composes, leur utilisation, et procede pour les produire
EP1924571B1 (fr) * 2005-08-30 2010-10-13 Boehringer Ingelheim International Gmbh Derives benzyl-benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de preparation
RU2008113050A (ru) 2005-09-08 2009-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
TW200801029A (en) * 2006-02-15 2008-01-01 Boehringer Ingelheim Int Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
MX2008014512A (es) * 2006-05-19 2008-11-27 Taisho Pharma Co Ltd Compuesto de c-fenil glucitol para el tratamiento de diabetes.
US8039441B2 (en) 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
WO2008055870A1 (fr) * 2006-11-06 2008-05-15 Boehringer Ingelheim International Gmbh Dérivés de benzyl-benzonitrile substitués par glucopyranosyle, médicaments contenant de tels composés, leur utilisation et procédé pour leur fabrication
NZ598778A (en) 2006-11-09 2013-09-27 Boehringer Ingelheim Int Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
WO2010092125A1 (fr) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp-iv et facultativement un autre agent antidiabétique et ses utilisations
US20140303097A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) * 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina

Also Published As

Publication number Publication date
BRPI1013640A2 (pt) 2019-09-24
AU2010212865A1 (en) 2011-07-21
SG173587A1 (en) 2011-09-29
US20120196812A1 (en) 2012-08-02
JP2017052787A (ja) 2017-03-16
CA2751833A1 (fr) 2010-08-19
SG10201600204YA (en) 2016-02-26
PE20120002A1 (es) 2012-02-12
US20160158264A1 (en) 2016-06-09
GEP20146120B (en) 2014-07-25
CA2751833C (fr) 2018-11-06
EP2396005A1 (fr) 2011-12-21
TN2011000413A1 (en) 2013-03-27
CL2011001757A1 (es) 2011-10-28
NZ594485A (en) 2013-07-26
US20200069713A1 (en) 2020-03-05
JP2015042691A (ja) 2015-03-05
CN104138370A (zh) 2014-11-12
JP2012517975A (ja) 2012-08-09
US20210283156A1 (en) 2021-09-16
KR20170028452A (ko) 2017-03-13
JP5896276B2 (ja) 2016-03-30
US20170020907A1 (en) 2017-01-26
CO6410306A2 (es) 2012-03-30
TWI478935B (zh) 2015-04-01
KR20110118668A (ko) 2011-10-31
US20220313716A1 (en) 2022-10-06
AU2010212865A8 (en) 2011-11-17
PH12016501607A1 (en) 2017-10-18
UA106365C2 (ru) 2014-08-26
MY161472A (en) 2017-04-14
ECSP11011275A (es) 2011-09-30
MX2011008214A (es) 2011-11-29
HK1203814A1 (en) 2015-11-06
MX344264B (es) 2016-12-09
CN102316875A (zh) 2012-01-11
WO2010092123A8 (fr) 2011-06-30
AP2011005795A0 (en) 2011-08-31
EA201101189A1 (ru) 2012-03-30
US20140031301A1 (en) 2014-01-30
EA021796B1 (ru) 2015-09-30
TW201040194A (en) 2010-11-16
WO2010092123A1 (fr) 2010-08-19
AR075424A1 (es) 2011-03-30
IL213723A0 (en) 2011-07-31
US20110046087A1 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
MA33043B1 (fr) Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
TW200716140A (en) Treatment of inflammatory conditions
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
EP2217596B8 (fr) Dérivés hétérocycliques bicycliques et leur utilisation en tant que modulateurs de l'activite du gpr 119
WO2009026657A8 (fr) Agonistes flavonoïdes de ppar
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IN2012DN02737A (fr)
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
WO2009117421A3 (fr) Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2011065982A3 (fr) Polymorphismes associés à la maladie de parkinson
MY172372A (en) Compositions and methods for lowering triglycerides
WO2010088518A3 (fr) Modulateurs hétérocycliques du gpr119 pour le traitement de maladies
IN2012DN02471A (fr)
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
WO2011014520A3 (fr) Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
WO2011127482A3 (fr) Modulation d'histone désacétylases pour le traitement d'une maladie métabolique, méthodes et compositions associées à celle-ci
EP2127668A4 (fr) Composition enzymatique et son utilisation
TN2013000187A1 (en) Pharmaceutical composition, methods for treating and uses thereof